Heart Transplantation Program News Today

In the first randomized trial comparing approaches, transplantation of hearts donated after circulatory death resulted in similar 6-month recipient survival as hearts donated after brain death.

InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01 - read this article along with other careers information, tips and advice on BioSpace

GuruFocus Article or News written by Stock market mentor and the topic is about:

Calgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has received a $250,000 Letter of Commitment

Calgary, Alberta--(Newsfile Corp. - October 26, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead

/PRNewswire/ -- Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve peoples health and the quality of patients...

Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC

/PRNewswire/ -- The International Society of Heart and Lung Transplantation has announced the results of the member election for the 2022 Board of Directors....